The Impact of Myelosuppression on Quality of Life of Patients Treated with Chemotherapy

Overview

Journal Future Oncol

Specialty Oncology

Date 2024 Apr 8

PMID 38587388

Authors

Jeffrey Crawford

Dana Herndon

Katerina Gmitter

Jared Weiss

Affiliations

Soon will be listed here.

Abstract

Side effects from chemotherapy-induced myelosuppression can negatively affect patients' quality of life (QoL). Neutropenia increases infection risk, and anemia frequently results in debilitating fatigue. Additionally, the bleeding risk associated with thrombocytopenia can lead to fear and anxiety. However, traditional interventions for myelosuppression fall short of the ideal. Granulocyte colony-stimulating factors reduce the risk of severe neutropenia but commonly lead to bone pain. Erythropoiesis-stimulating agents are not always effective and may cause thromboembolic events, while transfusions to correct anemia/thrombocytopenia are associated with transfusion reactions and volume overload. Trilaciclib, which is approved for reducing myelosuppression in patients with extensive-stage small cell lung cancer, together with several investigational agents in development for managing myelosuppression have the potential to improve QoL for patients on chemotherapy.

Citing Articles

Secondary Neutropenias.

Ward A Biomedicines. 2025; 13(2).

PMID: 40002910 PMC: 11853056. DOI: 10.3390/biomedicines13020497.

Metal Complexation for the Rational Design of Gemcitabine Formulations in Cancer Therapy.

Carnamucio F, Foti C, Cordaro M, Saija F, Cassone G, da Rocha S ACS Appl Mater Interfaces. 2024; 16(42):56789-56800.

PMID: 39378358 PMC: 11503523. DOI: 10.1021/acsami.4c12550.

Clinical Profiles, Laboratory Biomarkers, and Mortality in Cancer Patients with Lower Respiratory Tract Infections: A Prospective Cohort Study.

Radwan S, Mourad D, Hamdy R, Kamel M, Abdel-Moneim A, Elkhashab D Medicina (Kaunas). 2024; 60(6).

PMID: 38929518 PMC: 11205937. DOI: 10.3390/medicina60060901.

A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.

Hsu P, Wu B, Wang C, Chiu L, Chang C, Liu P Vaccines (Basel). 2024; 12(5).

PMID: 38793725 PMC: 11125689. DOI: 10.3390/vaccines12050474.

References

Barreto J, McCullough K, Ice L, Smith J . Antineoplastic agents and the associated myelosuppressive effects: a review. J Pharm Pract. 2014; 27(5):440-6. DOI: 10.1177/0897190014546108. View

Crawford J, Kosmidis P, Hirsch F, Langer C . Targeting anemia in patients with lung cancer. J Thorac Oncol. 2007; 1(7):716-25. View

Littlewood T, Bajetta E, Nortier J, Vercammen E, Rapoport B . Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001; 19(11):2865-74. DOI: 10.1200/JCO.2001.19.11.2865. View

Bendall L, Bradstock K . G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent. Cytokine Growth Factor Rev. 2014; 25(4):355-67. DOI: 10.1016/j.cytogfr.2014.07.011. View

Cella D, Kallich J, McDermott A, Xu X . The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol. 2004; 15(6):979-86. DOI: 10.1093/annonc/mdh235. View

Crawford J, Cella D, Cleeland C, Cremieux P, Demetri G, Sarokhan B . Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002; 95(4):888-95. DOI: 10.1002/cncr.10763. View

Epstein R, Weerasinghe R, Parrish A, Krenitsky J, Sanborn R, Salimi T . Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers. J Med Econ. 2021; 25(1):108-118. DOI: 10.1080/13696998.2021.2020570. View

Weycker D, Hatfield M, Grossman A, Hanau A, Lonshteyn A, Sharma A . Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC Cancer. 2019; 19(1):151. PMC: 6376753. DOI: 10.1186/s12885-019-5354-5. View

Epstein R, Basu Roy U, Aapro M, Salimi T, Moran D, Krenitsky J . Cancer Patients' Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life. Patient Prefer Adherence. 2021; 15:453-465. PMC: 7920579. DOI: 10.2147/PPA.S292462. View

10.

Lapidari P, Vaz-Luis I, Di Meglio A . Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review. Crit Rev Oncol Hematol. 2020; 157:103193. DOI: 10.1016/j.critrevonc.2020.103193. View

11.

Kenar G, Koksoy E, Urun Y, Utkan G . Prevalence, etiology and risk factors of anemia in patients with newly diagnosed cancer. Support Care Cancer. 2020; 28(11):5235-5242. DOI: 10.1007/s00520-020-05336-w. View

12.

Corey-Lisle P, Desrosiers M, Collins H, de la Orden M, Payne K, Briac Levache C . Transfusions and patient burden in chemotherapy-induced anaemia in France. Ther Adv Med Oncol. 2014; 6(4):146-53. PMC: 4107713. DOI: 10.1177/1758834014534515. View

13.

Blayney D, Mohanlal R, Adamchuk H, Kirtbaya D, Chen M, Du L . Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial. JAMA Netw Open. 2022; 5(1):e2145446. PMC: 8796017. DOI: 10.1001/jamanetworkopen.2021.45446. View

14.

Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M . Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016; 27(suppl 5):v111-v118. DOI: 10.1093/annonc/mdw325. View

15.

Weiss J, Goldschmidt J, Andric Z, Dragnev K, Gwaltney C, Skaltsa K . Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. Clin Lung Cancer. 2021; 22(5):449-460. DOI: 10.1016/j.cllc.2021.03.010. View

16.

Al-Samkari H, Parnes A, Goodarzi K, Weitzman J, Connors J, Kuter D . A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica. 2020; 106(4):1148-1157. PMC: 8018116. DOI: 10.3324/haematol.2020.251900. View

17.

Saleh M, Patel M, Bauer T, Goel S, Falchook G, Shapiro G . Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. Clin Cancer Res. 2021; 27(19):5236-5247. PMC: 9401461. DOI: 10.1158/1078-0432.CCR-21-0715. View

18.

Vadhan-Raj S . Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin Hematol. 2009; 46(1 Suppl 2):S26-32. DOI: 10.1053/j.seminhematol.2008.12.007. View

19.

Bisi J, Sorrentino J, Roberts P, Tavares F, Strum J . Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Mol Cancer Ther. 2016; 15(5):783-93. DOI: 10.1158/1535-7163.MCT-15-0775. View

20.

Crawford J, Denduluri N, Patt D, Jiao X, Morrow P, Garcia J . Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. Support Care Cancer. 2019; 28(2):925-932. PMC: 6954126. DOI: 10.1007/s00520-019-04875-1. View